Loading news...
/PRNewswire/ -- USA News Group News Commentary - Global capital is officially rotating into "Longevity Infrastructure" which is now valued at a massive $27
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf,” cell therapies for serious medical conditions, today announced the receipt of a novel, induced pluripotent stem cell (iPSC) line containing hypoimmunity edits, from Factor Bioscience Inc. (“Factor”). Generation of the line marks a successful milestone in the strategic collaboration between the two companies, un.
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf,” cell therapies for serious medical conditions, today published a letter to shareholders highlighting the company's achievements throughout 2025 and its corporate outlook for 2026. To Our Shareholders: As we conclude a successful 2025, I want to extend my appreciation for your continued support of Lineage Cell T.
Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Get Free Report) was up 4.7% on Tuesday. The company traded as high as $1.82 and last traded at $1.80. Approximately 1,331,886 shares traded hands during trading, an increase of 8% from the average daily volume of 1,228,101 shares. The stock had previously closed at $1.72. Analyst Ratings
Lineage Cell Therapeutics' OpRegen is partnered with Genentech/Roche. In my view, this is their main value driver in GA dry AMD. Looking ahead, their GAlette Phase 2a trial is enrolling, which could further validate the rest of their portfolio's potential. LCTX's pipeline also has OPC1 for spinal cord injury. Its preclinical R&D includes ANP1, PNC1, RND1, and ILT1.
Lineage Cell Therapeutics, Inc. ( LCTX ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Ioana Hone - Director of Investor Relations Brian Culley - CEO, President & Director Jill Howe - CFO & Principal Financial and Accounting Officer Conference Call Participants William Wood - B. Riley Securities, Inc., Research Division Joseph Pantginis - H.C.
Lineage Cell (LCTX) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.02 per share a year ago.
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today reported its third quarter 2025 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update. “It has been a productive third quarter for the Lineage team,” stated Brian.
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced that it will report its third quarter 2025 financial and operating results on Thursday, November 6, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, November 6, 2025, at.
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced the initiation of a new islet cell transplant program in Type 1 Diabetes (T1D). Specifically, the company aims to deploy its manufacturing capability to address the issue of large-scale production of islet cells, with the initial goal of establishin.
Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Brian M. Culley - CEO, President & Director Ioana C.
Lineage Cell (LCTX) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.03 per share a year ago.
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its second quarter 2025 financial and operating results on Tuesday, August 12, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Tuesday, August 12, 2025, at 4:30 p.m. Eastern T.
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious neurological and ophthalmic conditions, announced today that the first-ever chronic spinal cord injury patient has been treated in the Company's DOSED (Delivery of Oligodendrocyte Progenitor Cells (OPCs) for Spinal Cord Injury: Evaluation of a Novel Device) clinical study at UC San Di.
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious neurological and ophthalmic conditions, today announced that 36-month results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089) of RG6501 (OpRegen) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (.
Squarepoint Ops LLC acquired a new stake in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 92,001 shares of the company’s stock, valued at approximately $46,000. Several other institutional investors have also bought and sold shares of the company. Raffles Associates LP lifted its stake in Lineage Cell Therapeutics by 21.8% in the fourth quarter. Raffles Associates LP now owns 5,492,088 shares of the company’s stock valued at $2,760,000 after purchasing an additional 984,307 shares during the last quarter. Alyeska Investment Group L.P. purchased a new position in Lineage Cell Therapeutics in the fourth quarter valued at approximately $1,984,000. DAFNA Capital Management LLC lifted its stake in Lineage Cell Therapeutics by 85.9% in the fourth quarter. DAFNA Capital Management LLC now owns 2,511,374 shares of the company’s stock valued at $1,262,000 after purchasing an additional 1,160,666 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Lineage Cell Therapeutics by 1,058.3% in the fourth quarter. Renaissance Technologies LLC now owns 2,283,072 shares of the company’s stock valued at $1,147,000 after purchasing an additional 2,085,972 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new position in Lineage Cell Therapeutics in the fourth quarter valued at approximately $519,000. Hedge funds and other institutional investors own 62.47% of the company’s stock. Analyst Upgrades and Downgrades Several equities analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $9.00 price objective on shares of Lineage Cell Therapeutics in a research note on Tuesday, March 11th. D. Boral Capital reiterated a “buy” rating and issued a $2.00 price objective on shares of Lineage Cell Therapeutics in a research note on Tuesday, March 11th. Finally, B. Riley dropped their price objective on Lineage Cell Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a research note on Friday, March 14th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $4.20. View Our Latest Stock Report on LCTX Lineage Cell Therapeutics Price Performance NYSEAMERICAN:LCTX opened at $0.75 on Wednesday. The company has a market cap of $164.23 million, a P/E ratio of -6.21 and a beta of 1.21. The stock’s fifty day moving average price is $0.51 and its two-hundred day moving average price is $0.62. Lineage Cell Therapeutics, Inc. has a 1 year low of $0.37 and a 1 year high of $1.15. About Lineage Cell Therapeutics (Free Report) Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. See Also Five stocks we like better than Lineage Cell Therapeutics Overbought Stocks Explained: Should You Trade Them? AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway Should You Invest in Penny Stocks? Casey’s Surges on Strong Q4, More Gains Likely Ahead Options Trading – Understanding Strike Price Government Mandate Sends eVTOL Stocks Flying
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious neurological and ophthalmic conditions, today announced additional presenters to the 3rd Annual Spinal Cord Injury Investor Symposium ("3rd SCIIS"). The 3rd SCIIS will be a fully virtual event, with interactive and on-demand sessions available starting on June 27, 2025. “We are excite.
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage's Chief Executive Officer, will be presenting at the 3rd Annual H.C. Wainwright BioConnect Investor Conference, in a fireside chat hosted by Joseph Pantginis, Ph.D., Managing Director, Equity Research, on Tuesday, May 20, 2025, at 2:30pm ET. The 3rd Ann.
Lineage Cell (LCTX) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.04 per share a year ago.